Literature DB >> 25152583

Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Ahmet Bilici1.   

Abstract

The prognosis in patients with pancreatic cancer is poor and this cancer is the fourth leading cause of cancer-related death worldwide. Although surgical resection is the only curative treatment of choice for pancreatic cancer, the majority of patients are diagnosed at an advanced stage, thus only 10%-15% of them are suitable for curative resection and the overall survival is less than 5%. Chemotherapy for metastatic disease is to palliate symptoms of patients and to improve survival. Therefore, prognostic factors are important and a correct definition of poor prognostic factors may help to guide more aggressive adjuvant or aggressive treatment protocols in patients with pancreatic cancer. This article reviews the prognostic factors affecting survival of patients with pancreatic cancer in the light of recent advances in the literature.

Entities:  

Keywords:  Carbohydrate antigen 19-9; Pancreatic cancer; Prognostic factors; Survival; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25152583      PMCID: PMC4138460          DOI: 10.3748/wjg.v20.i31.10802

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  86 in total

1.  Tumor markers in pancreatic cancer: 2013.

Authors:  Urvi Ajay Shah; Muhammad Wasif Saif
Journal:  JOP       Date:  2013-07-10

2.  CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.

Authors:  Woong Sub Koom; Jinsil Seong; Yong Bae Kim; Hae Ok Pyun; Si Young Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-28       Impact factor: 7.038

3.  Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis.

Authors:  Marcos Vinicius Perini; Andre Luis Montagnini; Renata Coudry; Rosely Patzina; Sonia Penteado; Emilio Elias Abdo; Alessandro Diniz; Jose Jukemura; Jose Eduardo Monteiro da Cunha
Journal:  ANZ J Surg       Date:  2013-09-25       Impact factor: 1.872

Review 4.  Treatment for pancreatic cancer: current therapy and continued progress.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jordan D Berlin
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

5.  Obesity and survival in population-based patients with pancreatic cancer in the San Francisco Bay Area.

Authors:  Zhihong Gong; Elizabeth A Holly; Paige M Bracci
Journal:  Cancer Causes Control       Date:  2012-09-27       Impact factor: 2.506

6.  Adjuvant therapy in pancreatic cancer.

Authors:  Amy Thomas; Khaled Dajani; John P Neoptolemos; Paula Ghaneh
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

7.  Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Authors:  Minoru Oshima; Keiichi Okano; Shinobu Muraki; Reiji Haba; Takashi Maeba; Yasuyuki Suzuki; Shinichi Yachida
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.

Authors:  Johanna Louhimo; Henrik Alfthan; Ulf-Håkan Stenman; Caj Haglund
Journal:  Oncology       Date:  2004       Impact factor: 2.935

9.  Survival and prognostic factors of unresectable pancreatic cancer.

Authors:  Joo Kyung Park; Yong Bum Yoon; Yong-Tae Kim; Ji Kon Ryu; Won Jae Yoon; Sang Hyub Lee
Journal:  J Clin Gastroenterol       Date:  2008-01       Impact factor: 3.062

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  47 in total

1.  Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.

Authors:  Christof Kaltenmeier; Ibrahim Nassour; Richard S Hoehn; Sidrah Khan; Alison Althans; David A Geller; Alessandro Paniccia; Amer Zureikat; Samer Tohme
Journal:  J Gastrointest Surg       Date:  2020-12-02       Impact factor: 3.452

2.  Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.

Authors:  Makoto Kadokura; Yasuaki Ishida; Akihisa Tatsumi; Ei Takahashi; Hiroko Shindo; Fumitake Amemiya; Shinichi Takano; Mitsuharu Fukasawa; Tadashi Sato; Nobuyuki Enomoto
Journal:  J Gastrointest Oncol       Date:  2016-12

3.  Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer.

Authors:  Lingdi Yin; Linmei Xiao; Yong Gao; Guangfu Wang; Hao Gao; Yunpeng Peng; Xiaole Zhu; Jishu Wei; Yi Miao; Kuirong Jiang; Zipeng Lu
Journal:  Med Oncol       Date:  2020-04-10       Impact factor: 3.064

4.  Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib.

Authors:  Jae Min Lee; Hong Sik Lee; Jong Jin Hyun; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yeon Seok Seo; Yoon Tae Jeen; Hoon Jai Chun; Soon Ho Um; Chang Duck Kim
Journal:  World J Gastrointest Oncol       Date:  2016-07-15

5.  High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival.

Authors:  Qingqing Wang; Qichao Ni; Xudong Wang; Huijun Zhu; Zhiwei Wang; Jianfei Huang
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

6.  Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.

Authors:  Shuichi Ota; Mamiko Miyashita; Yuka Yamagishi; Masahiro Ogasawara
Journal:  Hum Vaccin Immunother       Date:  2021-12-17       Impact factor: 3.452

Review 7.  The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.

Authors:  Cameron J Herting; Isaac Karpovsky; Gregory B Lesinski
Journal:  Cancer Metastasis Rev       Date:  2021-09       Impact factor: 9.264

8.  Integration of Protein-Protein Interaction Networks and Gene Expression Profiles Helps Detect Pancreatic Adenocarcinoma Candidate Genes.

Authors:  Lili Su; Guang Liu; Ying Guo; Xuanping Zhang; Xiaoyan Zhu; Jiayin Wang
Journal:  Front Genet       Date:  2022-05-26       Impact factor: 4.772

9.  A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Raju Kandimalla; Hideo Tomihara; Jasjit K Banwait; Kensuke Yamamura; Gagandeep Singh; Hideo Baba; Ajay Goel
Journal:  Clin Cancer Res       Date:  2020-03-31       Impact factor: 12.531

10.  Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.

Authors:  Raju Kandimalla; Tadanobu Shimura; Saurav Mallik; Fuminori Sonohara; Susan Tsai; Douglas B Evans; Song Cheol Kim; Hideo Baba; Yasuhiro Kodera; Daniel Von Hoff; Xi Chen; Ajay Goel
Journal:  Ann Surg       Date:  2022-01-01       Impact factor: 13.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.